INMB PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

INMB ▲ +18.85% at T+20d

LONG call ✓ call won +18.85% · α vs SPY +11.23% · entry $1.22 → $1.45

Next anchor: T+60d tomorrow

Currently $1.24 · +1.64% from $1.22 entry

Entry anchored
Mar 18, 03:59 PM ET
via Databento tick

T+1d

-4.10%

call -4.10% · α -2.36%

$1.17

settled 3mo ago

T+5d

-1.64%

call -1.64% · α +0.57%

$1.20

settled 3mo ago

T+20d

+18.85%

call +18.85% · α +11.23%

$1.45

settled 8w ago

T+60d

—

call — · α —

—

tomorrow

Price Chart

Loading chart...

Executive Summary

INmune Bio highlighted positive biomarker-enriched Phase 2 MINDFuL trial results for XPro1595 in Alzheimer’s disease during a plenary presentation at AD/PD 2026 by respected neuroimmunologist Dr. Malú Gámez Tansey. The company is advancing to an integrated Phase 2b/3 registrational trial with FDA alignment, leveraging the same precision patient selection strategy. While no financials were disclosed, the validation from a key scientific opinion leader and regulatory progress represent meaningful clinical and strategic momentum.

Actionable Insight

Traders should monitor upcoming clinical trial milestones, including initiation of the Phase 2b/3 program and any future data releases. The endorsement by Dr. Tansey and FDA alignment de-risk development slightly, but the lack of disclosed numerical results limits immediate catalyst strength. Watch for insider trading activity and potential financing needs given the company's small market cap ($76M) and clinical-stage status.

Key Facts

Dr. Malú Gámez Tansey featured INmune Bio’s Phase 2 MINDFuL trial of XPro1595 in a plenary talk at AD/PD 2026, a top neurodegenerative disease conference.
The trial used a biomarker-enrichment strategy to select Alzheimer’s patients with peripheral inflammation, resulting in consistent efficacy signals across endpoints.
INmune Bio is advancing to an integrated Phase 2b/3 registrational program with FDA alignment following a successful End-of-Phase 2 meeting.
XPro1595 selectively inhibits soluble TNF without affecting trans-membrane TNF, differentiating it from existing TNF inhibitors.
No financial results or numerical efficacy data were disclosed in the press release.

Financial Impact

No direct financial impact disclosed; potential long-term value creation if Phase 2b/3 confirms clinical benefit and leads to approval.

revenuevaluationcash runway

Risk Factors

Company is pre-revenue and dependent on clinical trial success and external financing.
No quantitative efficacy data was provided; results remain anecdotal despite scientific endorsement.
High risk inherent in Phase 2/3 development, including potential for future trial failure or regulatory delays.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3258912

6 reports for INMB

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for INMB — sortable, filterable
	Type				Now
Jun 2, 2026 10d ago	8-K BULLISH ★ 7/10	$1.32 $1.35	▲ +2.27%	▲ +1.87%	$1.24 (−6.06%)
May 7, 2026 5w ago	Press Release MIXED ★ 4/10	$1.43 $1.35	▼ −5.59%	▼ −5.83%	$1.24 (−13.29%)
May 5, 2026 5w ago	8-K NEUTRAL ★ 4/10	$1.52 $1.43	▼ −5.92%	▼ −5.59%	$1.24 (−18.42%)
Apr 30, 2026 6w ago	Press Release BEARISH ★ 6/10	$1.43 $1.51	▼ −5.59%	▼ −5.37%	$1.24 (+13.29%)
Mar 30, 2026 10w ago	Press Release MIXED ★ 6/10	$1.13 $1.23	▲ +8.85%	▲ +8.10%	$1.24 (+9.73%)
Mar 19, 2026 12w ago	Press Release BULLISH ★ 7/10	$1.22 $1.17	▼ −4.10%	▼ −2.36%	$1.24 (+1.64%)

US Market Status

Market Closed — Opens Mon (48h 55m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access